Document is current
Any future updates will be listed below
-
Authors
Kealy, David https://orcid.org/0000-0001-9246-8134
Ellerington, Ruth https://orcid.org/0000-0001-7978-9873
Bansal, Suraj https://orcid.org/0000-0003-4023-6635
Medeiros, Jessie J. F. https://orcid.org/0000-0001-6597-4613
Hawley, Catherine A.
Zeng, Andy G. X.
Lukaszonek, Jakub
West, Katie A.
Sinha, Aparna D. https://orcid.org/0000-0001-5184-1326
Caalim, Gillian
Gawne, Richard T.
Pope, Jacob https://orcid.org/0009-0004-8970-0456
Ferreira, Bianca Lima https://orcid.org/0000-0001-7578-2244
Blacknell, Nicole-Mae https://orcid.org/0009-0007-5241-2575
Drylie, Bryce
Chatzigerou, Jenny https://orcid.org/0009-0008-0063-0295
Khoo, Hwei Minn
Wilkinson, Adam C.
Fielding, Adele K. https://orcid.org/0000-0002-4746-7789
Wang, Guanlin
Psaila, Bethan https://orcid.org/0000-0001-8198-9663
Kent, David G. https://orcid.org/0000-0001-7871-8811
Hitchcock, Ian S.
Holding, Andrew N. https://orcid.org/0000-0002-8459-7048
Mason, Andrew S. https://orcid.org/0000-0002-8222-3974
Gupta, Vikas https://orcid.org/0000-0002-1419-8607
Dick, John E.
Bridge, Katherine S. https://orcid.org/0000-0003-1516-1459
-
Funding
Funding for this research was provided by:
Kay Kendall Leukaemia Fund (KKL1377)
RCUK | Medical Research Council (UKRI1444)
Wellcome Trust (302479/Z/23/Z)
UKRI Medical Research Council grant (MC_PC_21043)
- License Information
-
More Information
Article History
Received: 28 January 2025
Revised: 21 November 2025
Accepted: 12 December 2025
First Online: 2 February 2026
Competing interests
: CAH and KSB are listed as inventors on patent application GB2515076.4 submitted in 2025 by the University of York, which covers targeting of the JAK2V617F oncogene by lipid nanoparticle–RNA therapeutics in vivo. CAH is a co-founder and shareholder of Antigonie Biosciences. ISH receives research funding from Incyte Corporation. BP is a co-founder and major shareholder of Alethiomics; has received honoraria for speaking engagements and/or advisory work for Incyte, BMS, Constellation Therapeutics, GSK, Blueprint Medicines, Novartis, and Alethiomics; and has received research funding from Incyte, Galecto, and Alethiomics. VG reports consultancy with AbbVie, Bristol Myers Squibb/Celgene, Novartis, Pfizer, Daiichi Sankyo, GSK, Incyte; data safety or advisory board participation with AbbVie, Bristol Myers Squibb/Celgene, GSK, Incyte; honoraria from Bristol Myers Squibb/Celgene, Novartis; research support from Novartis, AbbVie. JED has licensing agreements with Trillium Therapeutics and Pfizer for SIRP-a and has a sponsored research agreement with BMS. KSB is a co-founder and major shareholder of Antigonie Biosciences. JED reports receiving a commercial research grant from Celgene/BMS and has patents licensed to Trillium Therapeutics/Pfizer.
: All methods described in this manuscript were performed in accordance with the relevant guidelines and regulations. 172 JAK2V617F positive patients included in this study were part of a 358-patient study [ ] identified from the MPN registry at the Princess Margaret Cancer Centre (ClinicalTrials.gov Identifier: NCT02760238), from whom peripheral blood mononuclear cells (PB-MNCs) were collected at the first visit to Princess Margaret. Inclusion criteria consisted of a diagnosis of MF, including PMF, pre-fibrotic MF, post-ET MF, or post-PV MF in chronic phase. Individuals were excluded if they received a diagnosis of MPN-Unclassified (MPN-U), MPN/myelodysplastic syndrome (MDS) overlap, or lacked a biospecimen. All biological samples were collected under Research Ethics Board approval (REB#17-5601) with written informed consent as per the Declaration of Helsinki and were viably frozen in the Princess Margaret, hematologic malignancies tissue bank.
